Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Gross Margin (2022 - 2025)

bioAffinity Technologies has reported Gross Margin over the past 4 years, most recently at 43.49% for Q4 2025.

  • Quarterly Gross Margin rose 1425.0% to 43.49% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 31.4% through Dec 2025, down 468.0% year-over-year, with the annual reading at 31.4% for FY2025, 468.0% down from the prior year.
  • Gross Margin was 43.49% for Q4 2025 at bioAffinity Technologies, up from 34.84% in the prior quarter.
  • Over five years, Gross Margin peaked at 93.75% in Q2 2023 and troughed at 19.92% in Q2 2025.
  • The 4-year median for Gross Margin is 41.29% (2024), against an average of 54.74%.
  • Year-over-year, Gross Margin crashed -6776bps in 2023 and then skyrocketed 1425bps in 2025.
  • A 4-year view of Gross Margin shows it stood at 92.54% in 2022, then plummeted by -73bps to 24.78% in 2023, then rose by 18bps to 29.24% in 2024, then surged by 49bps to 43.49% in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Gross Margin are 43.49% (Q4 2025), 34.84% (Q3 2025), and 19.92% (Q2 2025).